The therapeutic potential of CETP inhibitors: a patent review

Area of Science:

• Biochemistry
• Pharmacology
• Cardiovascular Medicine

Background:

• High low-density lipoprotein-cholesterol (LDL-C) and low high-density lipoprotein-cholesterol (HDL-C) are independent risk factors for cardiovascular disease (CVD).
• Current CVD treatments like statins have limitations, creating a need for novel therapeutic strategies.
• Cholesteryl ester transfer protein (CETP) facilitates the transfer of cholesteryl esters from HDL to LDL and VLDL, influencing lipid profiles.

Purpose of the Study:

• To review the development and therapeutic applications of CETP inhibitors.
• To highlight patents and pharmaceutical applications of CETP inhibitors between 2009 and 2017.
• To assess the recent progress and challenges of CETP inhibitors in managing atherosclerosis-related diseases.

Main Methods:

• Comprehensive literature review focusing on patents and pharmaceutical applications.
• Analysis of clinical trial data for CETP inhibitors (torcetrapib, anacetrapib, evacetrapib, dalcetrapib).
• Evaluation of the efficacy of CETP inhibitors in raising HDL-C and reducing cardiovascular events.

Main Results:

• Four CETP inhibitors have undergone Phase III clinical trials, demonstrating success in elevating HDL-C levels.
• Despite raising HDL-C, these inhibitors showed suboptimal performance in reducing the overall risk of cardiovascular events.
• The direct correlation between elevated HDL-C levels and reduced CVD incidence requires further investigation.

Conclusions:

• CETP inhibitors have shown potential in modulating HDL-C levels but have not yet translated into significant reductions in cardiovascular event risk.
• The therapeutic timeline for CETP inhibitors in clinical practice for CVD remains uncertain.
• Further research is essential to validate the role of HDL-C in CVD and to refine CETP inhibitor strategies.